CAR macrophage therapy for advanced clear cell kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new treatment made from your own immune cells, modified to target a protein called CA9 that is common on clear cell kidney cancer cells. The cells are injected directly into a tumor, and the goal is to see if this can shrink the tumor or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced clear cell kidney cancer that has not responded to or has come back after at least one standard treatment.
- At least one of your tumors can be safely injected with a needle under ultrasound guidance.
- Your tumor shows signs of the CA9 protein.
- You are generally well enough to have blood cells collected and to receive the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medicine called HS-IT101 for people with advanced kidney cancer that hasn't responded to standard treatments. The goal is to see if this new therapy can help shrink or control the cancer.
This Phase 1 trial tests a new cell therapy called LNK001 in patients with advanced clear-cell kidney cancer that has progressed despite prior immunotherapy and targeted drugs. The therapy is designed to recognize and attack cancer cells by targeting a protein called CAIX.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial is testing whether adding a gut health supplement (CBM588) to the immunotherapy drug pembrolizumab can help prevent kidney cancer from returning after surgery. It is for people with certain types of kidney cancer who have not had immunotherapy before.
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
This trial tests a new type of cell therapy (CAR-NK cells) designed to target kidney cancer that has spread or cannot be removed with surgery. The cells are engineered in the lab to recognize and attack cancer cells, and may help patients whose cancer has grown despite previous treatments.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.